Yingen Biotechnology-B (09606) plans to repurchase up to $40 million worth of shares. Founder Zhu Zhongyuan plans to increase his shareholding by no more than $5 million.

The Smart Finance APP reports that Enzon Pharmaceuticals-B (09606) announced that the board of directors plans to exercise the power under the general authorization granted by the shareholders at the annual general meeting to be held on June 20, 2025, to repurchase company shares on the open market at an appropriate time. The share buyback plan aims to utilize up to $40 million to repurchase shares. The company will use internal funds to provide funding for the share buyback and intends to hold the repurchased shares as treasury shares.